Dose reductions of vincristine in children with medulloblastoma treated in the maintenance arm of the prospective multicenter trial HIT'91

Klin Padiatr. 2009 Nov-Dec;221(6):396-7. doi: 10.1055/s-0029-1238278. Epub 2009 Nov 4.
No abstract available

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Age Factors
  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Antineoplastic Agents, Phytogenic / toxicity*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / toxicity*
  • Cerebellar Neoplasms / drug therapy*
  • Cerebellar Neoplasms / mortality
  • Cerebellar Neoplasms / radiotherapy
  • Child
  • Child, Preschool
  • Cisplatin / administration & dosage
  • Cisplatin / toxicity
  • Combined Modality Therapy
  • Disease-Free Survival
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Lomustine / administration & dosage
  • Lomustine / toxicity
  • Male
  • Medulloblastoma / drug therapy*
  • Medulloblastoma / mortality
  • Medulloblastoma / radiotherapy
  • Neoadjuvant Therapy
  • Nervous System Diseases / chemically induced*
  • Nervous System Diseases / prevention & control*
  • Prospective Studies
  • Radiotherapy, Adjuvant
  • Risk Factors
  • Vincristine / administration & dosage*
  • Vincristine / toxicity*

Substances

  • Antineoplastic Agents, Phytogenic
  • Vincristine
  • Lomustine
  • Cisplatin